These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

933 related items for PubMed ID: 30617090

  • 1. Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae.
    Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y, Nguyen MH, Clancy CJ, Shields RK.
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [Abstract] [Full Text] [Related]

  • 2. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM, Antochevis LC, Magagnin CM, Arns B, Vieceli T, Pereira DC, Lutz L, de Souza ÂC, Dos Santos JN, Guerra RR, Medeiros GS, Santoro L, Falci DR, Rigatto MH, Barth AL, Martins AF, Zavascki AP.
    J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472
    [Abstract] [Full Text] [Related]

  • 3. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS.
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M.
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [Abstract] [Full Text] [Related]

  • 5. Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment.
    Romanelli F, Stolfa S, Morea A, Ronga L, Prete RD, Chironna M, Santacroce L, Mosca A.
    Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.
    Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ.
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242667
    [Abstract] [Full Text] [Related]

  • 7. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M.
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS, Baek JY, Ko J-H, Cho SY, Lee KY, Lee YH, Yang J, Kim TY, Huh HJ, Lee NY, Huh K, Kang C-I, Chung DR, Peck KR.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0034424. PubMed ID: 38687076
    [Abstract] [Full Text] [Related]

  • 9. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P, Re MC, Campoli C, Viale PL, Ambretti S.
    Clin Microbiol Infect; 2020 Apr 04; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [Abstract] [Full Text] [Related]

  • 10. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
    Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O.
    Antimicrob Agents Chemother; 2017 Dec 04; 61(12):. PubMed ID: 29038260
    [Abstract] [Full Text] [Related]

  • 11. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
    Bedenić B, Sardelić S, Bogdanić M, Zarfel G, Beader N, Šuto S, Krilanović M, Vraneš J.
    Arch Microbiol; 2021 May 04; 203(4):1825-1831. PubMed ID: 33507339
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.
    Cabello M, Hernández-García M, Maruri-Aransolo A, Michelena M, Pérez-Viso B, Ponce-Alonso M, Cantón R, Ruiz-Garbajosa P.
    J Glob Antimicrob Resist; 2024 Sep 04; 38():281-291. PubMed ID: 38996870
    [Abstract] [Full Text] [Related]

  • 17. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
    Venditti C, Butera O, Meledandri M, Balice MP, Cocciolillo GC, Fontana C, D'Arezzo S, De Giuli C, Antonini M, Capone A, Messina F, Nisii C, Di Caro A.
    Clin Microbiol Infect; 2021 Jul 04; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
    [Abstract] [Full Text] [Related]

  • 18. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.
    Jacobs MR, Abdelhamed AM, Good CE, Mack AR, Bethel CR, Marshall S, Hujer AM, Hujer KM, Patel R, van Duin D, Fowler VG, Rhoads DD, Six DA, Moeck G, Uehara T, Papp-Wallace KM, Bonomo RA.
    Antimicrob Agents Chemother; 2024 Sep 04; 68(9):e0075124. PubMed ID: 39133021
    [Abstract] [Full Text] [Related]

  • 19. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring blaKPC-14 Isolated in New York City.
    Niu S, Chavda KD, Wei J, Zou C, Marshall SH, Dhawan P, Wang D, Bonomo RA, Kreiswirth BN, Chen L.
    mSphere; 2020 Aug 26; 5(4):. PubMed ID: 32848008
    [Abstract] [Full Text] [Related]

  • 20. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan 26; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.